Enhancing Support for Women With Type 2 Diabetes: Follow-Up
This study is a 5-year continuation of "The Mediterranean Lifestyle Program." The purpose of this follow-up study is to determine the long-term effects from prior participation in an intervention promoting healthful eating, exercise, quitting smoking, stress management, and social support. Participants are post-menopausal women with type 2 diabetes.
Type 2 Diabetes Mellitus
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Enhancing Support for Women With Type 2 Diabetes: Follow-Up|
- Food Frequency Questionnaire for Fruits, Vegetables and percent calories from fat (FFQ) by Kristal and colleagues [ Time Frame: annually, 36 months - 84 months ] [ Designated as safety issue: No ]
- Lipids, weight loss [ Time Frame: annually, 36 months - 84 months ] [ Designated as safety issue: No ]
|Study Start Date:||December 2003|
|Study Completion Date:||December 2009|
|Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
Treatment condition from first study. This is a follow-up study.
Control condition from first study.
Coronary heart disease (CHD) is the leading cause of death and functional limitations among women in the U.S. Postmenopausal women with diabetes are at especially high risk of CHD, but CHD research with this population is very limited. This project addresses the poorly understood "natural history" of long-term maintenance of change in multiple behaviors (i.e., dietary, physical activity, social support, smoking cessation, and stress management) related to CHD risk, as well as the effects of theoretically important mediating variables on relapse and maintenance. The study is a continuation of a research project that has already demonstrated significant and consistent positive effects of a lifestyle change intervention on reduction of behavioral CHD risk factors. This research relies on a framework that synthesizes social-cognitive, social-ecologic, and goal-systems theories.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00680849
|United States, Oregon|
|Oregon Research Institute|
|Eugene, Oregon, United States, 97403|
|Principal Investigator:||Deborah J. Toobert, Ph.D.||Oregon Research Institute|